Related references
Note: Only part of the references are listed.Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody
John E. Leonard et al.
MOLECULAR CANCER THERAPEUTICS (2015)
SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease
Ernest S. Smith et al.
NEUROBIOLOGY OF DISEASE (2015)
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jerome Galon et al.
IMMUNITY (2013)
ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis
Thomas Worzfeld et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Roles of Sema4D and Plexin-B1 in tumor progression
Ewe Seng Ch'ng et al.
MOLECULAR CANCER (2010)
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
Satish L. Deshmane et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2009)
Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
Jose Rafael Sierra et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
The Semaphorin 4D receptor controls invasive growth by coupling with Met
S Giordano et al.
NATURE CELL BIOLOGY (2002)
Biological activity of soluble CD100.: II.: Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration
S Delaire et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
